Essays can be submitted from September 26, 2012 to November 9, 2012.For more information visit www.Anaphylaxis101.com. Get Schooled in Anaphylaxis™ The Get Schooled in Anaphylaxis™ initiative offers practical information to educate the school community to help those at risk for life-threatening allergic reactions avoid their triggers, recognize anaphylaxis signs and symptoms and understand how to quickly get appropriate treatment and immediate medical care when anaphylaxis occurs. Visit www.Anaphylaxis101.com to explore how anaphylaxis can affect the entire school community and learn more about life-threatening allergic reactions. You can also download practical tools, learn more about Julie Bowen's family story and watch a PSA featuring the actress, and sign up to receive news about campaign activities and events. More About AnaphylaxisAnaphylaxis is a life-threatening allergic reaction that can occur when the body is exposed to an allergen. Symptoms may include trouble breathing, chest pain, skin hives or redness of the skin, tightness in the throat, swelling of the lips and/or tongue, nausea, dizziness, a decrease in blood pressure, and/or fainting. Anaphylaxis symptoms may progress rapidly and become life-threatening, requiring prompt recognition and treatment initiation. While avoidance of allergic triggers is the critical first step in managing life-threatening allergies, allergens are not always obvious, and accidental exposure may still happen. Food allergy guidelines developed by National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), recommend epinephrine as the only first-line treatment for anaphylaxis management and that it be available at all times to those at risk for anaphylaxis. If experiencing anaphylaxis, a person should use an epinephrine auto-injector and seek immediate emergency medical attention. Delays in instituting therapy with epinephrine are associated with risks of death and morbidity. About Mylan SpecialtyMylan Specialty, a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more information, please visit www.mylanspecialty.com. About MylanMylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide seven billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. Mylan.com. Get Schooled in Anaphylaxis™ and Get Schooled in Anaphylaxis Challenge™ are sponsored by and trademarks of Mylan Specialty L.P. © 2012. All rights reserved. MYS12-8001 SOURCE Mylan, Inc.